Up to 42% of patients thought to be in low or moderate disease activity were found to be in high disease activity when measured by the Vectra® test and also at risk for joint damage. The Vectra® test helps identify risk so action can be taken earlier.
Evaluate the success of controlling inflammation by using the Vectra® test and monitoring the scores over time.
An evaluation that combines the molecular measures of biomarkers with the patient and rheumatologist assessments provides the most comprehensive approach to inform treatment decisions.
The Vectra® test now accounts for age, gender and adiposity for a more personalized score.
The Vectra® test is the best predictor of future joint damage. The adjusted Vectra® test score was validated in four cohorts combined as a superior prognostic of radiographic progression, compared with conventional measures.
The Vectra® test can inform the success of treatment when scores are tracked over time. A change in 8 or more units in subsequent Vectra® test scores reflects a meaningful change and may be considered a tool, combined with a clinical assessment, to optimize treatment decision-making.
Evaluate the success of controlling RA inflammation by using the Vectra® test at initiation of treatment, change in drug treatment or to monitor response to therapy.
Download the brochure to learn more about the Vectra® test and how it can help to improve patient and provider decisions.
The Vectra® test report gives a molecular assessment of RA disease. The Vectra® test demonstrates its unsurpassed ability to predict radiographic progression as a personalized inflammatory measure for patients with RA. The Vectra® test is a validated, advanced blood test performed by a CLIA-certified laboratory.
Rheumatology Services Hotline: 800-338-1918
Vectra® Customer Service: 877-743-8639
